Video

Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study

Author(s):

Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Related Videos
Matthew P. Deek, MD
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Thach-Giao Truong, MD
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Lorenza Rimassa, MD
Related Content
RP1 Plus Nivolumab in Advanced Melanoma
November 22nd 2024

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Lung Cancer
November 11th 2024

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors